After the pandemic revealed deep disparities in health outcomes, pharma has turned its attention to health equity with razor sharp focus. Learn the latest initiatives to diversify trials in this Trendline.
Pharma has turned its attention to health equity with razor-sharp focus in recent years. A new wave of strategies are beginning to flood the industry, including better approaches to recruiting diverse populations, attempts to overcome negative perceptions of research and efforts to take trials directly to patient communities.
Included in this trendline
- What should pharma make of the FDA going dark on DEI?
- FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.
- Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Offered Free by: PharmaVoice and Quest Diagnostics
See All Resources from: PharmaVoice and Quest Diagnostics
